In vitro and in vivo evaluation of anti-HER2 antibody conjugates labelled with 225Ac

In vitro and in vivo evaluation of anti-HER2 antibody conjugates labelled with 225Ac

Abstract Background Overexpression of human epidermal growth factor receptor type 2 (HER2) occurs in multiple carcinomas. For example, up to 20% of breast cancer cases are classified as HER2 positive (HER2+). Treatment of this condition typically involves immunotherapy using monoclonal antibodies, s...

Full description

Saved in:
Bibliographic Details
Main Authors: Kateřina Ondrák Fialová, Lukáš Ondrák, Martin Vlk, Ján Kozempel, Kateřina Nováková, Zbyněk Nový, Katarína Hajduová, Marián Hajdúch, Miloš Petřík, Marek Pruszynski, Frank Bruchertseifer, Alfred Morgenstern
Format: Article
Language:English
Published: SpringerOpen 2025-04-01
Series:EJNMMI Radiopharmacy and Chemistry
Subjects:
HER2
Pertuzumab
Trastuzumab
Actinium-225
Targeted alpha therapy
SKOV-3
Online Access:https://doi.org/10.1186/s41181-025-00337-8
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s41181-025-00337-8

Similar Items